Cyclosporine Research History: Discovery, Key Trials and Regulatory Timeline

Cyclosporine is a prescription medicine. It is dispensed under medical supervision, and its approved indications, labelling and monitoring requirements are set by national regulators. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about whether a medicine is appropriate for a particular person. Nothing below describes doses, schedules or treatment decisions, it summarises what the cited published literature reports, in chronological order of publication.

Origins: A Cyclic Peptide of Fungal Origin

The chemical identity of cyclosporine is the starting point of its research history. A 2015 review of cyclosporin semi-synthesis described the cyclosporins as naturally occurring cyclic peptides obtained from fungal sources, and set out how that natural scaffold became a template for chemical modification (PMID 25707381). The same 2015 review explained that the natural product is structurally complex, which is why medicinal chemists pursued semi-synthetic routes rather than total synthesis when generating analogues (PMID 25707381).

Popular accounts of who first isolated cyclosporine, in which year, and at which laboratory are reported in historical sources that fall outside the citation set used on this page. Because every dated claim here must carry a PubMed link, this page states only what the cited papers support: the cyclosporins are fungal natural products that were developed into clinically used immunosuppressant chemistry (PMID 25707381). Readers who want named-investigator attribution should consult primary historical reviews and the regulator's own product records.

From Natural Product to Semi-Synthetic Chemistry

The 2015 semi-synthesis review is the clearest published statement of how cyclosporine chemistry developed after the original fermentation product entered medicine. Researchers summarised the strategies used to modify the cyclic peptide ring in order to generate derivatives with altered properties, an approach that only became possible once the parent molecule was available in quantity (PMID 25707381). That review frames cyclosporine not as a single fixed entity but as the head of a chemical family, which is relevant when reading later literature that compares analogues (PMID 25707381).

Transplantation: The Field That Defined the Early Clinical Record

Transplant medicine is where the published record on cyclosporine is densest. A 2016 history of lung transplantation reviewed the sequence of surgical and pharmacological developments that moved the procedure from repeated early failure toward routine practice, and placed the arrival of cyclosporine-era immunosuppression among the changes that reshaped the field in the 1980s (PMID 29404127). The authors of that historical review treated immunosuppressive pharmacology as inseparable from surgical progress, because graft survival depended on controlling rejection (PMID 29404127).

Later immunology literature continued to use cyclosporine as the reference immunosuppressant against which newer agents were described. A 2021 paper on thymodepressin, an immunosuppressive peptide, positioned its discussion within the established class of immunosuppressive agents to which cyclosporine belongs (PMID 34770959). That framing shows how, decades after its introduction, cyclosporine remained the comparator in the published literature on new immunosuppressors (PMID 34770959).

Ophthalmology: Corneal Transplantation Studies

Corneal grafting generated its own cyclosporine literature, split between systemic and topical administration. A 2015 review in Cornea examined topical cyclosporine in corneal transplantation and summarised what the published studies reported about its place in graft management (PMID 25357076). A 2016 review in International Ophthalmology covered the parallel question of systemic cyclosporine and corneal transplantation, assembling the published evidence on systemic administration in that setting (PMID 26463642).

Read together, these two reviews mark a stage in the research history where investigators were no longer asking whether cyclosporine suppressed rejection in principle, but which route of administration suited a specific graft type, a question the 2016 systemic review addressed directly (PMID 26463642). Neither review is a basis for self-directed decisions; both describe clinician-supervised ophthalmic practice (PMID 25357076).

Dermatology: The Psoriasis Literature

Cyclosporine appears throughout the systemic psoriasis literature as an established oral agent. A 2015 review of emerging oral drugs for psoriasis described the existing systemic options against which newer oral candidates were being measured (PMID 25643592). A 2017 review of treatment approaches to moderate-to-severe psoriasis set out the same landscape in more detail, covering conventional systemic therapy alongside biologic alternatives (PMID 29144382).

The most recent dermatology citation on this page, a 2024 review of cytokines in psoriasis, traced the condition from pathogenesis through to targeted therapy and illustrates how mechanistic understanding has moved toward cytokine-specific intervention (PMID 38768527). That trajectory is part of cyclosporine's history too: the broad immunosuppressant preceded the targeted agents described in the 2024 cytokine review (PMID 38768527).

Haematology: Severe Aplastic Anaemia Regimens

In severe aplastic anaemia, cyclosporine is a component of standard immunosuppressive regimens, and the modern literature is largely about what happens when those regimens do not produce an adequate response. Two 2018 publications reported on the activity of eltrombopag in severe aplastic anaemia, with the Blood Advances report describing the drug's activity in disease that persisted despite immunosuppressive therapy (PMID 30425070). The companion 2018 ASH education programme article covered the same question for a clinical-education audience (PMID 30504345).

These reports matter to the research history because they document the point at which cyclosporine-containing immunosuppression became the backdrop rather than the subject, researchers were asking what to add, not whether to use immunosuppression at all (PMID 30425070).

Neurology: Investigation in Traumatic Brain Injury

The most recent research direction in the cited set is neurological. A 2023 review in Neurotherapeutics examined cyclosporine as a candidate therapy for traumatic brain injury and summarised the preclinical and clinical investigation conducted in that indication (PMID 37561274). This line of work is investigational and distinct from the transplant and dermatology indications; the 2023 review discussed it as an area of continuing study rather than settled practice (PMID 37561274).

Chronology of the Cited Literature

The table below lists the publications cited on this page in date order. It is a chronology of the cited evidence, not a complete bibliography of cyclosporine research.

Adverse Events in the Cyclosporine Literature: What Studies Report

Case reporting is part of any medicine's research history. A 2018 case report in Cureus described cyclosporine-induced erythromelalgia, documenting the reaction in a patient receiving the medicine (PMID 30648046). Single case reports such as this one establish that an event has been observed and reported; they do not establish how often it occurs (PMID 30648046).

Broader safety considerations in specific indications are discussed inside the clinical reviews already cited, for example, the 2016 review of systemic cyclosporine in corneal transplantation addressed the systemic-administration context in ophthalmic patients (PMID 26463642), and the 2017 psoriasis review discussed conventional systemic therapy within the wider treatment landscape (PMID 29144382). The complete, current safety profile for any approved cyclosporine product is contained in that product's regulator-approved labelling, and questions about it belong with a prescribing clinician.

Regulatory Status, Stated Positively

Cyclosporine is a prescription medicine. Approved formulations include oral and ophthalmic products, and each approval is tied to specific indications, labelling, and monitoring requirements defined by the relevant national regulator. Exact approval dates and indication wording are held in regulatory approval records and product labelling rather than in the review literature cited here, so this page does not assign dates to them. The clinical reviews cited above describe cyclosporine in supervised medical use across transplantation (PMID 29404127), ophthalmology (PMID 25357076) and dermatology (PMID 25643592), while the 2023 neurotherapeutics review describes traumatic brain injury as an area of continuing investigation (PMID 37561274).

How to Read This History

• Chemistry first. The cyclosporins are fungal cyclic peptides whose complexity shaped how analogues were made (PMID 25707381).
• Transplantation set the template. The 2016 lung transplantation history treats immunosuppression as central to the field's progress (PMID 29404127).
• Indications widened, then narrowed. Ophthalmic and dermatologic reviews explored route and setting (PMID 26463642), while targeted cytokine therapy later reshaped psoriasis practice (PMID 38768527).
• Newer questions are additive. The 2018 aplastic anaemia reports asked what to add to immunosuppression, not whether to use it (PMID 30504345).

Readers looking for a general orientation to cyclosporine rather than its chronology can consult the cyclosporine overview page on PeptideU. For any question about suitability, interactions, monitoring or alternatives, a prescribing clinician is the correct source.

References

• Semi-synthesis of cyclosporins (Biochimica et Biophysica Acta, 2015)
• Topical cyclosporine in corneal transplantation (Cornea, 2015)
• Emerging oral drugs for psoriasis (Expert Opinion on Emerging Drugs, 2015)
• Systemic cyclosporine and corneal transplantation (International Ophthalmology, 2016)
• History of Lung Transplantation (Turkish Thoracic Journal, 2016)
• Treatment Approaches to Moderate to Severe Psoriasis (International Journal of Molecular Sciences, 2017)
• Cyclosporine-induced Erythromelalgia (Cureus, 2018)
• Activity of eltrombopag in severe aplastic anemia (Blood Advances, 2018)
• Activity of eltrombopag in severe aplastic anemia (Hematology ASH Education Program, 2018)
• Thymodepressin-Unforeseen Immunosuppressor (Molecules, 2021)
• Cyclosporine as Therapy for Traumatic Brain Injury (Neurotherapeutics, 2023)
• Cytokines in psoriasis: From pathogenesis to targeted therapy (Human Immunology, 2024)